21 November 2023 - The chance of survival for hundreds of Australians living with a deadly type of blood cancer is in the hands of a government committee, which will decide whether to support public funding for a ­revolutionary therapy that could send their cancer into remission with a single infusion.

It’s the second time the Medical Services Advisory Committee has been asked to approve public funding of the new drug cilta-cel, sold as Carvykti, for multiple myeloma, with the lives of 300 patients who have failed conventional treatments hanging in the balance. The committee meets to consider the application on Wednesday.

Read The Australian article